Ryan J. Sullivan
YOU?
Author Swipe
View article: Real‐World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations
Real‐World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic Mutations Open
Purpose A significant proportion of patients with locoregional (stage III) cutaneous melanoma recur despite adjuvant systemic therapy. Staging criteria and surgical nodal management have changed since the trials were completed. Data assess…
View article: Table 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Table 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients Open
Demographics and baseline characteristics.
View article: Supplementary Data 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Supplementary Data 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients Open
Contains all supplementary tables and figures
View article: Figure 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Figure 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients Open
Attenuation of select TRAE with repeated dosing. Incidence and severity of select TRAE over time for patients with mUM treated with tebentafusp across all studies (N = 410). A, Weekly incidence of TRAE during the acute phase …
View article: Table S2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Table S2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial Open
Summary of anti-tumor activity endpoints in patients treated with eganelisib monotherapy and combination therapy
View article: Table S4 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Table S4 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial Open
Representativeness of Study Participants
View article: Censoring rules 3 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Censoring rules 3 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial Open
Study IPI-549-01 progression-free survival censoring rules for efficacy analyses
View article: Inclusion and Exclusion Criteria 1 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Inclusion and Exclusion Criteria 1 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial Open
Study IPI-549-01 full protocol inclusion and exclusion criteria
View article: Table S1 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Table S1 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial Open
Geometric mean (geometric CV%) of eganelisib PK parameters in patients with solid tumors in the monotherapy cohort
View article: Methodology and Criteria for MDSCs 2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Methodology and Criteria for MDSCs 2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial Open
Study IPI-549-01 methodology and criteria for assessing MDSCs
View article: 609 Restoring immune responsiveness in periphery and tumor with mRNA-4359, an mRNA-based therapy encoding PD-L1 and IDO1 peptides, plus pembrolizumab in checkpoint inhibitor resistant/refractory melanoma
609 Restoring immune responsiveness in periphery and tumor with mRNA-4359, an mRNA-based therapy encoding PD-L1 and IDO1 peptides, plus pembrolizumab in checkpoint inhibitor resistant/refractory melanoma Open
View article: 380 Cutaneous eruptions associated with lifileucel, a first-in-class tumor-infiltrating lymphocyte therapy, and interleukin-2 in individuals with metastatic melanoma: a retrospective prognostic analysis
380 Cutaneous eruptions associated with lifileucel, a first-in-class tumor-infiltrating lymphocyte therapy, and interleukin-2 in individuals with metastatic melanoma: a retrospective prognostic analysis Open
View article: RADT-42. NASCENT CLINICAL EXPERIENCE WITH RADIOTHERAPEUTIC MANAGEMENT OF MELANOMA BRAIN METASTASES IN PATIENTS TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY
RADT-42. NASCENT CLINICAL EXPERIENCE WITH RADIOTHERAPEUTIC MANAGEMENT OF MELANOMA BRAIN METASTASES IN PATIENTS TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY Open
Tumor-infiltrating lymphocyte (TIL) therapy is an emerging treatment option for treatment-refractory melanoma. TIL therapy involves tumor harvest, isolation and ex vivo expansion of TILs, followed by lymphodepletion prior to infusion. TIL …
View article: INNV-13. Real-world outcomes in patients with brain metastases secondary to melanoma treated with nivolumab and relatlimab
INNV-13. Real-world outcomes in patients with brain metastases secondary to melanoma treated with nivolumab and relatlimab Open
PURPOSE Patients with melanoma brain metastases (MBM) have a poor prognosis despite improvements in treatments. The combination of ipilimumab and nivolumab remains the standard of care for this patient population and there is limited data …
View article: Understanding tumor-immune-stromal dynamics driving response and resistance to immune checkpoint blockade in melanoma 4125
Understanding tumor-immune-stromal dynamics driving response and resistance to immune checkpoint blockade in melanoma 4125 Open
Description Melanoma patients treated with anti-PD1 or anti-PD1/anti-CTLA4 present intrinsic or acquired resistance to these immune checkpoint blockade (ICB) treatments. However, the interactions between tumor-stromal-immune cells in the m…
View article: 1316 Initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR β-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a phase 1/2 trial
1316 Initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR β-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a phase 1/2 trial Open
View article: P11.19.B NASCENT CLINICAL EXPERIENCE WITH RADIOTHERAPEUTIC MANAGEMENT OF MELANOMA BRAIN METASTASES IN PATIENTS TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY
P11.19.B NASCENT CLINICAL EXPERIENCE WITH RADIOTHERAPEUTIC MANAGEMENT OF MELANOMA BRAIN METASTASES IN PATIENTS TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY Open
BACKGROUND Tumor-infiltrating lymphocyte (TIL) therapy is an emerging treatment option for treatment-refractory melanoma, FDA-approved in 2024. TIL therapy involves tumor harvest, isolation and ex vivo expansion of TIL, followed by lymphod…
View article: Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients
Concurrent local therapy extends clinical benefit of tebentafusp in metastatic uveal melanoma patients Open
Background Tebentafusp has significantly improved overall survival in HLA-A*02:01+ metastatic uveal melanoma (mUM) patients even in those with a best objective response of progressive disease. Thus, strategies to maintain tebentafusp thera…
View article: Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients Open
Purpose: We conducted an integrated safety analysis from three clinical studies of tebentafusp, a first-in-class ImmTAC bispecific T-cell engager, which can redirect T cells to target glycoprotein 100–positive cells, in metastatic uveal me…
View article: Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma
Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma Open
View article: Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes
Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes Open
Immune checkpoint inhibitors (ICIs) have improved survival of patients with cancer, yet they pose risks of immune-related adverse events (irAEs). ICI-induced insulin-dependent diabetes mellitus (ICI-DM) is a life-threatening and life-alter…
View article: RDTA-20 BRAIN-DIRECTED RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH MELANOMA BRAIN METASTASES TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY
RDTA-20 BRAIN-DIRECTED RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH MELANOMA BRAIN METASTASES TREATED WITH TUMOR-INFILTRATING LYMPHOCYTE (TIL) THERAPY Open
PURPOSE Tumor-infiltrating lymphocyte (TIL) therapy is an emerging option for treatment-refractory melanoma. Studies for TIL therapy approval excluded patients with uncontrolled melanoma brain metastases (MBMs). Given the timeline from TIL…
View article: Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants
Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants Open
View article: Dual Checkpoint Blockade in Merkel Cell Carcinoma: Lessons from CheckMate 358 and the Questions That Remain
Dual Checkpoint Blockade in Merkel Cell Carcinoma: Lessons from CheckMate 358 and the Questions That Remain Open
View article: Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma Open
Response to immune checkpoint inhibitors (ICIs) in metastatic melanoma (MM) varies among patients, and current baseline biomarkers predicting treatment outcomes are limited. As mitochondrial (MT) metabolism has emerged as an important regu…
View article: First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer
First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer Open
Background mRNA-2416 is a novel lipid nanoparticle-encapsulated messenger RNA (mRNA) encoding human OX40 ligand (OX40L) for intratumoral (Itu) injection. OX40L plus immune checkpoint inhibitor (ICI) increased preclinical antitumor activity…
View article: SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy Open
Cancer immunotherapy has radically changed the management of several malignancies, and dozens of agents have been approved in the past 15 years. While these advances have changed the field, many challenges lie ahead and must be addressed i…
View article: Impact evaluation and program development of a severe immunotherapy complications fellowship: the Massachusetts General Cancer Center Experience
Impact evaluation and program development of a severe immunotherapy complications fellowship: the Massachusetts General Cancer Center Experience Open
View article: Tumor location as a risk factor for severe immune-related adverse events
Tumor location as a risk factor for severe immune-related adverse events Open
Immune-related adverse events (irAEs) can cause severe morbidity and mortality, and they impair treatment with immune checkpoint inhibitors (ICI). Risk factors for irAEs are not well understood. We observed cases of patients having tumor d…
View article: Multimodal blood based profiling reveals insights into mechanisms of immunotherapy resistance
Multimodal blood based profiling reveals insights into mechanisms of immunotherapy resistance Open
Many cancer patients treated with immune checkpoint blockade (ICB) do not have durable treatment responses. Circulating biomarkers have the potential to identify patients with primary resistance or early progression on therapy to alter tre…